Sirukumab
![☒](http://upload.wikimedia.org/wikipedia/commons/thumb/a/a2/X_mark.svg/7px-X_mark.svg.png)
![check](http://upload.wikimedia.org/wikipedia/en/thumb/f/fb/Yes_check.svg/7px-Yes_check.svg.png)
Sirukumab (INN, USAN) (developmental code name CNTO-136, tentative brand name Plivensia) is a human monoclonal antibody designed for the treatment of rheumatoid arthritis.[1] It acts against the proinflammatory cytokine Interleukin 6 (IL-6).[2]
Sirukumab is currently under development by Johnson & Johnson's subsidiary Centocor.[3]
Clinical trials
Rheumatoid arthritis
It has started clinical trials.[4] and reported some phase II results.[3]
In December 2015 three phase III trials (SIRROUND-D, -H and -T) were collecting data.[5] By Feb 2017 SIRROUND-D was considered to have met both co-primary endpoints.[6]
Research
The drug was previously under development for the treatment of depression.[7]
References
- ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Sirukumab" (PDF). American Medical Association.
- ^ Bartoli F, Bae S, Cometi L, Matucci Cerinic M, Furst DE (July 2018). "Sirukumab for the treatment of rheumatoid arthritis: update on sirukumab, 2018". Expert Review of Clinical Immunology. 14 (7): 539–547. doi:10.1080/1744666X.2018.1487291. PMID 29925278. S2CID 49330982.
- ^ a b "Interleukin-6 Inhibitor Sirukumab (CNTO 136) Phase 2 Data Show Promise in the Treatment of Active Rheumatoid Arthritis". PR News Wire. Cision. 25 May 2011.
- ^ Clinical trial number NCT00718718 for "A Study of the Effectiveness and Safety of CNTO 136 in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy" at ClinicalTrials.gov
- ^ House DW (16 December 2015). "Glaxo says top-line results positive in late-stage study of sirukumab in rheumatoid arthritis". Seeking Alpha.
- ^ "IL-6 in RA: What Predicts Non-Progression? - High-risk patients showed most benefit with sirukumab". January 2017.
- ^ "Sirukumab - Janssen Biotech". AdisInsight. Springer Nature Switzerland AG.
- v
- t
- e
(initiation)
Antimetabolites |
|
---|---|
Macrolides/ other IL-2 inhibitors | |
IMiDs |
(reception)
IL-1 receptor antagonists | |
---|---|
mTOR |
Antibodies |
| ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
-cept (Fusion) |
- Avacopan
- Baricitinib
- Bimekizumab
- Blisibimod
- Briakinumab
- Brodalumab
- Canakinumab
- Crovalimab
- Danicopan
- Darvadstrocel
- Deucravacitinib
- Dimethyl fumarate
- Diroximel fumarate
- Efgartigimod alfa (+hyaluronidase)
- Etrasimod
- Filgotinib
- Fingolimod
- Guselkumab
- Iptacopan
- Itacitinib
- Ixekizumab
- Netakimab
- Olokizumab
- Ozanimod
- Peficitinib
- Pegcetacoplan
- Pirfenidone
- Ponesimod
- Ravulizumab
- Risankizumab
- Ritlecitinib
- Rozanolixizumab
- Sarilumab
- Satralizumab
- Siltuximab
- Siponimod
- Sirukumab
- Spesolimab
- Sutimlimab
- Tildrakizumab
- Tofacitinib
- Upadacitinib
![]() | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e
![]() | This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e